Ignite Creation Date:
2024-05-05 @ 5:15 PM
Last Modification Date:
2024-10-26 @ 9:29 AM
Study NCT ID:
NCT00413959
Status:
TERMINATED
Last Update Posted:
2018-09-19
First Post:
2006-12-19
Brief Title:
VELCADERituximabCyclophosphamide and Decadron
Sponsor:
Oncology Specialists SC
Organization:
Oncology Specialists SC
Study Overview
Official Title:
Phase II Study Investigating the Efficacy of VELCADE Rituximab Cyclophosphamide and Decadron VRCD Regimen in Front-line Therapy of Patients With Low-grade Non-Hodgkins Lymphoma
Status:
TERMINATED
Status Verified Date:
2018-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
VRCD
Brief Summary:
Overall response rate and Time to disease progression using this regimen in patients with low-grade B-Cell Non-Hodgkins Lymphoma
Detailed Description:
This is a phase II open label study that is looking at the VRCD combination regimen in patients with previously untreated low-grade Non-Hodgkins Lymphoma Treatment will start by combining oral dexamethasone and cyclophosphamide with intravenous VELCADE rituximab Chemotherapy cycles will be given as outlined below every 35-days and will continue until two cycles beyond complete remission CR toxicity patients withdrawal disease progression or a maximum of 8 cycles
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None